Trials / Completed
CompletedNCT04103333
Angelman Syndrome (AS) Biomarker Study
A Study to Explore Cerebrospinal Fluid and Blood Biomarkers in Participants With Angelman Syndrome
- Status
- Completed
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Biogen · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to measure ubiquitin-protein ligase E3A (UBE3A) protein levels in cerebrospinal fluid (CSF) and to evaluate its utility as a biomarker in support of the development of therapies for AS.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Lumbar Puncture | Administered as specified in the treatment arm. |
| PROCEDURE | Blood Collection | Administered as specified in the treatment arm. |
Timeline
- Start date
- 2019-12-18
- Primary completion
- 2022-01-02
- Completion
- 2022-01-02
- First posted
- 2019-09-25
- Last updated
- 2022-01-28
Locations
5 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT04103333. Inclusion in this directory is not an endorsement.